Better Space Stock: Rocket Lab vs. AST SpaceMobile (Hint: It Comes Down to Dilution)

Rocket Lab is presented as financially better positioned than AST SpaceMobile: Rocket Lab generated $769 million in revenue over the last 12 months and has $110 million in quarterly cash burn, while AST is burning more than $700 million per quarter. Rocket Lab's shares outstanding rose 33% over five years, versus 479% for AST; the article favors Rocket Lab, citing its revenue base and lower dilution.

Analysis

The relative case favors Rocket Lab’s operating exposure over AST SpaceMobile’s financing- and execution-sensitive optionality, but this article is not tradeable without verification. Its claim that Rocket Lab acquired Iridium is a critical, independently checkable premise; do not attribute Iridium’s revenue or cash generation to Rocket Lab unless a completed transaction and its financing, closing date, and consolidation treatment are confirmed. If no deal closed, the article’s cash-flow comparison is materially compromised. If one did, the key question shifts to purchase consideration, added leverage/dilution, and whether Iridium’s cash generation survives integration—not simply the headline cash flow.

Over the next 1–3 months, ASTS faces asymmetric downside if deployment delays or funding needs force another equity raise; successful launches and demonstrable service economics could sharply reverse the bearish setup. For RKLB, Neutron schedule, launch cadence, and segment-level cash burn matter more than broad space-economy sentiment. Over 6–18 months, execution can widen the gap: reliable launch and systems revenue may support RKLB’s investment cycle, while ASTS must prove coverage, telecom-partner monetization, and capital efficiency. Competitors and launch partners create both capacity risk and bargaining leverage; a launch bottleneck can delay ASTS revenue while also constraining other constellation operators.

Contrarian point: a large drawdown alone does not make ASTS cheap, but dilution may already be well recognized; a verified deployment acceleration could force a rapid repricing. Conversely, RKLB’s relative quality does not establish attractive valuation. No valuation or current market pricing is supplied, so avoid an unconditional long recommendation.

Key Decisions for Investors

• Treat the Iridium acquisition as an unverified thesis-critical claim. Confirm transaction status, consideration, financing, and consolidation in company filings before using Iridium cash flows in any RKLB model.
• Prefer RKLB to ASTS on operating visibility, but make any relative-value position conditional: consider a risk-sized long RKLB / short ASTS only after checking current valuation, borrow availability, and latest filings. Falsify the spread thesis if RKLB’s Neutron schedule or cash burn deteriorates materially, or ASTS demonstrates sustained deployment progress without a dilutive raise.
• For ASTS, monitor unrestricted cash, quarterly net cash use, committed launch slots, satellites deployed, and partner revenue terms. A financing announcement or further launch slippage is a downside catalyst; verified commercial service and improving unit economics are the key upside invalidators.
• Do not infer an immediate buy from the drawdowns. Reassess after the next filings and launch updates; the article supplies no price, valuation, or independently verified cash-flow data to support a price target or defined options trade.